START Midwest is included in START’s global network of Phase I clinical research sites, which currently includes two centers in Madrid¬†and START’s flagship site in San Antonio, which opened in 2007. START Midwest is START’s second US-based site, and will offer advanced cancer patients first-ever access to investigational, Phase I medicines.

START Midwest has over 15,000 square feet of dedicated space located on the ground floor suite of Cancer & Hematology Centers of Western Michigan (CHCWM) EAST location in Grand Rapids, Michigan.

START Midwest is led by Dr. Nehal Lakhani and brings the latest treatment options to cancer patients in Western Michigan and throughout the Midwest.

Prior to START Midwest opening, patients in West Michigan who wanted access to early phase anti-cancer drugs had to travel to Ann Arbor, Detroit or Chicago. Now, late-stage cancer patients in Grand Rapids have access to early phase medicines without having to travel.

Our Mission

The mission of START is to accelerate the development of new anticancer drugs that will improve the quality of life and survival for patients with cancer. Our drug development program is not only furthering cancer research, but also offers hope to patients facing the toughest cancer battles.